Relugolix/Estradiol/Norethindrone Acetate

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRelugolix/Estradiol/Norethindrone Acetate
Drug Alias NameRelugolix combination tabletrelugolix + estradiol + norethindrone acetateEstradiol/norethisterone acetate/relugolixEstradiol/norethindrone acetate/relugolixLow-dose hormonal add-back +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGonadotropin-releasing hormone receptor antagonistsProgesterone receptor agonistsEstrogen receptors agonists +[4] 
TargetsEstrogen receptorsSignal-regulatory protein alphaProgesterone receptor +[4] 
Therapy Area/IndicationsUterine FibroidsPainMenorrhagia +[6] 
Global Approved IndicationsUterine FibroidsMenorrhagiaLeiomyoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/26
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsYes EstradiolRelugolixNorethindrone Acetate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMyovant Sciences
China Registration ClassN/A

Develop Information

Active CompaniesGedeon RichterSumitomo Pharma America IncMyovant Sciences +[6] 
Inactive CompaniesN/A
Active IndicationsUterine FibroidsPainMenorrhagia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeH01CC
Related LinksN/A